is part of the Informa Markets Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Saudi Arabia is striving to become a more attractive investment destination for multinational pharmaceutical companies through economic development projects that facilitate doing business. Furthermore, increased medical insurance coverage, a growing population, higher living standards, and the rising incidence of non-communicable diseases are all factors driving additional demand for pharmaceuticals within the country. The Kingdom has outlined an ambitious plan in the run up to 2030, with the goal of becoming a pharma hub for the entire Middle East region.
Click on the below video to learn more!
Saudi Arabia’s health sector transformation: can it advance the domestic manufacture of pharmaceuticals?
In this podcast interview, Musaed Alkholief, Associate Professor at the College of Pharmacy, King Saud University, and Consultant at King Abdullah Institute for Research and Consulting Studies discusses how biopharmaceutical companies can unlock those undoubted opportunities presented by the proposed transformation of Saudi Arabia’s health sector.
Informa Markets, the organisers of the leading regional pharmaceutical event CPhI Middle East & Africa, (CPhI MEA), has announced the 2020 edition of the show will be held alongside the Global Health Exhibition (GHE) in Riyadh, Saudi Arabia on 26-28 September 2021. Under the patronage of HE Dr. Tawfiq Al Rabiah, Saudi Arabia’s Minister of Health, the move to Saudi Arabia and taking place in conjunction with GHE, will create a larger platform for the regional pharma community and underscores the commitment of the country to the global pharmaceutical industry.
CPhI Middle East & Africa is closely monitoring developments concerning the Coronavirus COVID-19. The health and safety of both our customers and colleagues is always our top priority. As such, we are following all safety advice and precautions as recommended by local Departments of Health, as well as the World Health Organization (WHO).
CPhI Middle East & Africa 2019, the global pharmaceutical showcase held in Abu Dhabi, has concluded after welcoming 234 exhibiting companies and over 3,100 visitors, from 98 countries. His Excellency Sheikh Nahyan bin Mubarak al Nahyan, Minister of Tolerance, opened the event on 16 September, amid the projected US$41 billion the pharmaceutical industry in the MENA region is expected to top by 2022.
Abu Dhabi, United Arab Emirates, 18 September 2019: CPhI Middle East & Africa concluded today at the Abu Dhabi National Exhibition Centre (ADNEC) with a panel discussion addressing the UAEs commitment to becoming an innovative market while effectively managing healthcare spending in the region.
CPhI pharma event hosts discussion on how Saudi Arabia pharmaceutical industry is helping to deliver the country’s Vision 2030. The Saudi pharma market is the largest across the MENA region with a market size of US$7.5 billion with a growth expected at a CAGR of around 5.5% according to experts.
His Excellency Sheikh Nahyan bin Mubarak al Nahyan, Minister of Tolerance, inaugurates CPhI Middle East & Africa 2018. Global industry professionals descend upon ADNEC in Abu Dhabi for the region’s leading platform for the pharmaceutical sector.
The event, which is returning for a second year after its successful launch in the capital last year, will take place at the Abu Dhabi National Exhibition Centre (ADNEC) from 16-18 September 2019. Sponsored by the Ministry of Health and Protection (MoHaP), CPhI is set to attract attendees from the Middle East and Africa (MEA) - of which the MENA region accounts for 4% of the global pharma market - and the rest of the world.
Saudi Arabia’s pharmaceutical market expected to grow at a CAGR of 5.5% until 2023. Growing population, increase in non-communicable diseases and major investment in new hospitals, clinics and treatments driving growth.
PRIDE CHEMTECH DMCC is a pharmaceutical solutions provider with expertise in product development services and raw materials supplies. Ranked as the number one global free zone in 2019 by fDi Magazine, the DMCC Free Zone is the ideal location from which to provide our local and international clients with branded generic dossiers, technology transfers, raw materials supplies and regulatory services.
Qualicaps® is a supplier of two-piece hard capsules to the Pharmaceutical and Health & Nutrition industry. Qualicaps® has 5 manufacturing sites globally, with the European headquarters in Madrid, Spain. It is fully owned by Mitsubishi Chemical corporation, Japan.
PromoPharma, founded in San Marino in 1998, offers the widest range of effective and safe solutions in the field of Soft Therapies with food supplements, dietary foods for special medical purposes and medical devices.
Neopharma LLC UAE, is one of the largest pharmaceutical companies in the MENA region with wholly owned subsidiaries in the US, Japan, Brazil, the UK and India. It is a vertically integrated business, comprising of Key Intermediaries, API, R&D and Formulation facilities in regulated and emerging markets.
The MENA (Middle East and North Africa) region is a largely untapped, yet potentially hugely fruitful part of the world for the pharmaceutical industry, both as a sales region and for the establishment of manufacturing facilities. Some multinational corporations have already started to invest directly into the region – namely into Saudi Arabia, the most economically powerful country in MENA.